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INCREASED CD4CD25HIGH REGULATORY T-CELL ARE ASSOCI-
ATED WITH DISEASE RELAPSE AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION (SCT) FOR CHRONIC MYELOID LEUKAEMIA (CML)
Nadal, E.1,2, Kaeda, J.1, Apperley, J.F.1, Lechler, R.2, Dazzi, F.1,2
1Haematology Department Hammersmith Hospital, Imperial College,
London, United Kingdom; 2Immunology Department Hammersmith
Hosppital, Imperial College, London, United Kingdom.
The success of SCT after CML largely relies on the graft versus
leukaemia (GvL) effect exert by donor T-cells. CD4CD25 regu-
latory T-cell (Tregs) play a crucial role in the maintenance of periph-
eral tolerance and have been tested in animal models to successfully
prevent GVHD. The role of Tregs in clinical transplantation remains
unclear, insofar as the few studies published to date have reported
controversial results regarding GvHD. Although there is emerging
evidence that Tregs are associated with a poor outcome in cancer
patients, none of these studies has investigated the role of Tregs in
leukaemia relapse post-SCT.
To address this question we quantiﬁed CD4CD25high regula-
tory T-cells in post-SCT patients and correlated their levels with
clinical outcome.
We performed a cross-sectional study at a single institution. We
enumerated and characterised peripheral blood CD4CD25high
Tregs in 76 patients after allogeneic SCT for CML by FACS
analysis. As control we analysed 21 samples from healthy volun-
teers and 20 samples from newly diagnosed CML patients. BCR-
ABL/ABL ratio was determined in every sample by real-time PCR.
Patients were considered in remission if the ratio was less than
0.02% and in relapse if higher. All quoted p-values are two-sided
with P0.05 considered statistically signiﬁcant.
Patients after SCT had higher levels of Treg than normal donors
(median 1.5% vs 0.87, p0.01) and untreated CML (median 1.5% vs
0.27, p0.0001). In the multiple regression analysis only the time post
SCT (before or after 18 months) and disease status (molecular remis-
sion versus relapse) were predictive for increased Tregs (Coef -2.994,
p0.004 and Coef -2.395, p0.020 respectively). No association with
Treg levels and GvHD was found. The logistic regression analysis
performed in 43 patients that had not received DLI post SCT con-
ﬁrmed that increased Tregs, both as percentage or absolute numbers,
were the only predictive variable for relapse (exp 1.44, p0.011).
A substantial expansion of Tregs occurs early after allogeneic
SCT and the presence of high numbers of Tregs 18 months after
transplant is predictive of leukaemic relapse. Although the incre-
ment might initially have an advantageous effect on graft rejection,
our data suggest that Tregs exert an inhibitory effect on GvL.
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PRESERVED ANTI-VIRAL RESPONSES AND IMPROVED SURVIVAL IN
STEROID REFRACTORY GVHD USING A COMBINATION OF DACLIZUMAB
AND INFLIXIMAB
Rao, K.1, Rao, A.1, Karlsson, H.2, Veys, P.1, Amrolia, P.1,2 1Great
Ormond Street Hospital, London, United Kingdom; 2Institute of Child
Health, London, United Kingdom.
Steroid refractory acute graft versus host disease (SRGvHD) is a
life threatening complication of SCT with poor prognosis due to
infection related mortality. We investigated the combined use of
Dacluzimab, a humanised monoclonal antibody (Mab) targeting
IL-2 and Inﬂiximab, a chimeric human/mouse anti-TNF a, in
order to selectively delete alloreactive cells and target 2 different
points in the cytokine cascade responsible for aGvHD.
Fifteen consecutive children (median age 4.5 years) with SRGvHD
(deﬁned as aGvHD that failed to improve after 1 week of at least
2mg/kg/day ofMethylprednisolone) were treated. Donors wereMSD
or MFD (n3), MUD (n9) and mismatched UD (n3). All 15
patients had involvement of the skin, 14 of the lower gut and 5 of the
liver. All patients had grade 3 (n5) or 4 (n10) GVHD. Patients
were treated with a combination of Daclizumab (1mg/kg, days
1,4,8,15,22) and Inﬂiximab (10mg/kg, days 1,8,15,22), with rapid
reduction of steroid dosage to 1mg/kg. Median time of starting the
Mabs was day 17 from the onset of GvHD. All children received
anti-fungal prophylaxis and prospective viral monitoring.
12/15 patients responded (7 CR, 5 PR), with a median response
time of 13 days. Two patients developed recurrent GvHD and
received a second course of Mabs. There were 10 episodes of viral
reactivations (CMV 4, adeno 3, EBV 3) and 3 patients developed
probable fungal infections. Impressively, however, there were no
infection related deaths. T-cell responses to CMV after mAb
infusion were assessed in 5 patients using the IFN-g ELISPOT
assay. As shown in the table below, 4 patients showed a signiﬁcant
response to CMV (deﬁned as 40 SFC per 2 105 PBMC) in the
ﬁrst 3 months after treatment and at least 1 patient (UPN2) was
able to mount a de novo response to CMV after mAb therapy.
At a median follow-up of 30 months, 10/15 (66%) children are
alive. 3 primary non-responders died of progressive GvHD, as did
1 patient who achieved a PR but subsequently developed bronchi-
olitis obliterans and 1 patient who died of Pseudomonas sepsis.
5/10 evaluable patients developed chronic GVHD (3 limited, 2
extensive), which has resolved in 2 cases. This data suggests that
combination treatment with Daclizumab and Inﬂiximab is a highly
effective therapeutic option for patients with SRGvHD and is
associated with preservation of anti-viral responses and a low in-
fection related mortality compared to standard therapies.
CMV-speciﬁc T-cell responses post- mAbs (IFN-gamma SFC/2 
10e5 PBMC)
Pre-mAbs 1 month 3 months
UPN 1 NE 0 41
UPN 2 0 2 98
UPN 13 81 138 23
UPN 14 NE 73 148
UPN 15 11 NE 0
Normal donor 68
NE not evaluated
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HISTONE DEACETYLASE INHIBITORS INDUCE INDOLEAMINE 2, 3-DI-
OXYGENASE AND MODULATE DENDRITIC CELL FUNCTIONS
Reddy, P.1, Sun, Y.1, Maeda, Y.1, Weisiger, E.1, Duran-Struuck, R.1,
Dinarello, C.2, Ferrara, J.L.1 1University of Michigan Medical Center,
Ann Arbor, MI; 2University of Colorado, Denver, CO.
Recent studies have demonstrated that suberoylanilide hydroxamic
acid (SAHA), a histone deacetylase (HDAC) inhibitor, reduces exper-
imental acute graft-versus-host disease (GVHD). We investigated the
cellular-molecular mechanisms of immuno-modulation by two
HDAC inhibitors, SAHA and ITF 2357. Stimulation of bone marrow
derived dendritic cells (DCs) with various TLR ligands (lipopolysac-
charide (LPS), PGN, CpG) after pretreatment with either SAHA
caused a signiﬁcant reduction in the secretion of TNF-, IL-12p70
and IL-6 compared to the untreated controls (P 0.01). Similar
effects were seen using human peripheral blood mononuclear cell
derived DCs. Pre-treatment of DCs also signiﬁcantly reduced their in
vitro and in vivo stimulation of allogeneic T cells as measured by
proliferation and IFN- production (P0.05), which was not reversed
by anti-IL-10 or anti-TGF. No signiﬁcant difference was observed
in the viability of pretreated and control DCs. Pretreatment signiﬁ-
cantly suppressed the expression of CD40 and CD80. When mixed
with normal DCs at 1:1 ratio, SAHA treated DCs suppressed alloge-
neic T cell responses in a contact dependent manner. When DCs
from B6 MHC Class II deﬁcient (H-2b) were treated with SAHA and
co-cultured with wild type B6 DCs along with puriﬁed allogeneic
BALB/c (H-2d) CD4 T cells in an MLR, the allo-CD4 T cells
proliferated demonstrating the regulation to be dependent on contact
between SAHA treated DCs and T cells. To determine the molecular
mechanism, we analyzed for the expression of indoleamine 2, 3-di-
oxygenase (IDO) and found that both SAHA and ITF 2357 increased
IDO at the mRNA and protein levels. A functional role for IDO was
conﬁrmed by the blockade of its induction with speciﬁc small inter-
fering RNA (siRNA) in SAHA mediated suppression if TNF- . To
address the in vivo relevance of this suppression, we utilized the
[BALB/c3B6] model of acute GVHD. B6 animals received 11Gy on
day -1 and injected with of 5 million B6 SAHA treated or control DCs
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on days -1, 0, and 2. Mice were transplanted with T cells and BM
from either syngeneic B6 or allogeneic BALB/c donors. Injection of
SAHA treated DCs resulted in better survival (60% vs. 10%, P 
0.05) and signiﬁcantly reduced serum levels of TNF- and donor T
cell expansion compared to the controls. Together our data demon-
strate a novel IDO dependent mechanism for HDAC inhibitor me-
diated immuno-modulation of DCs and regulation of GVHD.
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DONOR-REACTIVE THYMIC-DEPENDENT TH1 CELLS CAUSE CHRONIC
GVHD
Sakoda, Y.1,2, Hashimoto, D.3, Asakura, S.1, Takeuchi, K.4,
Harada, M.2, Tanimoto, M.1, Teshima, T.3 1Biopathological Science,
Okayama University Graduate School of Medicine and Dentistry,
Okayama, Japan; 2Department of Medicine and Biosystemic Science,
Kyushu University Graduate School of Medical Science, Fukuoka, Japan;
3Center for Cellular and Molecular Medicine, Kyushu University Hos-
pital, Fukuoka, Japan; 4Pathology, Japanese Foundation for Cancer
Institute, Tokyo, Japan.
Chronic graft-versus-host disease (GVHD) continues to be the
most common late complication after allogeneic bone marrow
transplantation (BMT) and the basic pathophysiology of chronic
GVHD remains poorly deﬁned. We have previously demonstrated
that donor bone marrow-derived T cells differentiated via im-
paired thymus of the recipients cause chronic GVHD after allo-
geneic transplantation of T cell-depleted bone marrow (TCD
BM). Lethally irradiated C3H/HeN (H-2k) recipients of TCD BM
cells from MHC class II-deﬁcient (H2Ab1-/-) B6 (H-2b) mice
developed GVHD showing clinical and histopathological features
of human chronic GVHD. We further studied mechanism of
chronic GVHD in this model. A ﬂowcytometric analysis showed
that the numbers of CD4CD25foxp3 regulatory T cells were
comparable between [WT3C3H] and [H2-Ab1-/-3 C3H] mice.
Thymectomy prevented chronic GVHD, thus suggesting the
causal association of the thymus. We then investigated reactivity of
pathogenic CD4 T cells in [H2-Ab1-/- 3 C3H] mice. A ﬂow
cytometric analysis of cell division of CFSE-labeled donor T cells
demonstrated that [H2-Ab1-/- 3 C3H] CD4 T cells divided to
B6 stimulators, but not to C3H stimulators. A ﬂowcytometric
analysis of intracytoplasmic IL-4 and IFN-g suggested polarization
of these cells toward Th1 cytokine responses. Adoptive transfer of
[H2Ab1-/-3 C3H] CD4 T cells caused severe and lethal disease
in B6 recipients. All mice died by day 40 post-BMT and a patho-
logical analysis of the liver and intestine showed standard patho-
logical features of acute GVHD. In contrast, the transfer of [H2-
Ab1-/-3 C3H] CD4 T cells did not cause GVHD in C3H
recipients. Thus, both in vitro and in vivo experiments demon-
strated that these pathogenic CD4 T cells were primarily B6
reactive. Interestingly, the transfer of these cells caused chronic
GVHD in C3H recipients similar to the primary [H2-Ab1-/- 3
C3H] mice in the presence of B6-derived antigen-presenting cells
(APCs). To further conﬁrm the requirement of B6-derived APCs
for the disease, we created [B6 3 C3H] and [C3H 3 C3H]
chimeras. The transfer of [H2-Ab1-/-3 C3H] CD4 T cells did
caused chronic GVHD only in the [B63 C3H] chimeras, but not
in the [C3H 3 C3H] chimeras, thus conﬁrming the requirement
of B6- derived APCs for the transmission of the disease to second-
ary recipients. These results suggest that self-reactivity of donor
Th1 cells play a role in this chronic GVHD.
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THE ALLO-REACTIVITY OF DONOR T-CELLS IS SHAPED BY THE PRES-
ENCE OF IMMUNOSTIMULATORY OR IMMUNOSUPPRESSIVE DONOR
DENDRITIC CELL SUBSETS IN THE GRAFT: IMPLICATIONS FOR GVHD
AND GVL IN BMT
Southerland, L.T.1, Li, J.-M.2, Waller, E.K.2 1Duke University,
Durham, NC; 2Emory University, Atlanta, GA.
The immunological activity of donor T-cells following alloge-
neic BMT is determined by the initial interaction of T-cells with
antigen presenting cells (APC) in the recipient. While previous
reports have established a requirement for host APC in the initi-
ation of GvHD, we have explored the role of donor APC as
positive and negative regulatory elements in the activation of allo-
reactive donor T-cells. We have previously published that alloge-
neic donor BM enriched for CD11b- dendritic cells (DC) pro-
motes enhanced donor T-cell chimerism and GvL, suggesting that
donor DC subsets modulate immune reconstitution post-BMT
(Li, Waller. BBMT 2004). In this study, we examined the immune
polarization capabilities and co-stimulator expression of FACS-
puriﬁed CD11b and CD11b- DC subsets in allogeneic BMT and
their effect on survival, GvL, GvHD, and immune reconstitution.
Fifty thousand puriﬁed CD11b DC or CD11b- DC from
C57BL/6 donors were transplanted along with 5,000 puriﬁed Lin-
,Sca-1,C-kit hematopoietic stem cells (HSC) and 300,000 con-
geneic spleen T-cells into C57BL/6 [H-2Kb] and B10BR [H-2Kk]
recipient mice. The cytokine production, immune proliferation,
and Ki-67 expression of CFSE-labeled donor T-cells were evalu-
ated. Additionally, DC subsets were analyzed by ﬂow cytometry for
co-stimulator expression, including PD-L1, PD-L2, CD80, and
CD86. In tumor free mice, recipients of HSC alone or HSC
combined with CD11b DC or CD11b- DC did not differ in
survival or GvHD over 100 days post allo-BMT. Recipients of
CD11b- DC had increased GvL and donor T-cell proliferation at
days 10, 30, 60, and 105, resulting in full-donor T-cell chimerism.
In contrast, recipients of CD11bDC had mixed T-cell chimerism
and increased numbers of immunosuppressive donor
CD4CD25Foxp3T-cells. Phenotypic and functional analysis
of CD11b and CD11b- DC revealed that CD11b DC had
higher levels of immunosuppressive co-stimulators PD-L1 and
PD-L2, while CD11b- DC induced higher levels of IL-12 and
IFN- when co-cultured with syngeneic T-cells. In conclusion,
donor CD11b- DC promote immune reconstitution and GvL and
polarize donor T-cells to Th1 immune responses, while donor
CD11b DC suppress immune reconstitution by expressing sup-
pressive co-stimulators and promoting tolerant donor Treg cells.
Donor Graft Cells and Survival
Experimental
Group
Number of
Mice
DC
Subset
Tumor
Cells
Survival
(100 days
post-BMT)
HSC alone 40 none none 90%
HSC alone 20 none LBRM 0%
HSC  T-cells 40 none none 80%
HSC  T-cells 20 none LBRM 0%
HSC  T-cells 
DC 40 CD11b- none 80%
HSC  T-cells 
DC 20 CD11b- LBRM 40%***
HSC  T-cells 
DC 40 CD11b none 80%
HSC  T-cells 
DC 20 CD11b LBRM 0%
HSC5,000 lin-, sca-1, c-kit bone marrow cells; T-cells
300,000 splenic T-cells; DC 50,000 FACS sorted CD11b- or
CD11b dendritic cell subsets; LBRM 100,000 T-lympho-
blastic leukemic cells; *** p0.01 compared to other groups
with LBRM
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PREDICTION OF ACUTE GRAFT VERSUS HOST DISEASE AFTER ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION BY A PRO-
TEOMIC AGVHD-SPECIFIC PATTERN
Weissinger, E.M.1, Schiffer, E.2, Hertenstein, B.1,3, Ferrara, J.L.4,
Holler, E.5, Stadler, M.1, Kolb, H.-J.6, Zander, A.7, Zuerbig, P.2,
Kellmann, M.8, Ganser, A.1 1Hannover Medical School, Hannover,
Germany; 2Mosaiques-Diagnostics GmbH, Hannover, Germany; 3Med-
ical Clinic I Klinikum Bremen Mitte, Bremen, Germany; 4University of
Michigan Medical School, Ann Abor, MI; 5University Hospital of Re-
gensburg, Regensburg, Germany; 6Ludwig-Maximillians University,
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